期刊
BIOMEDICINES
卷 10, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10102371
关键词
C. elegans; N-NOSE; multi-cancer screening; primary screening; olfaction; urine
Improving the rate and effectiveness of routine cancer screenings is a challenge in healthcare, but multi-cancer early detection (MCED) is a potentially effective solution. Using C. elegans as a biosensor for universal cancer screening, specifically with N-NOSE, has shown promising results.
Regular cancer screening is critical for early cancer detection. Cancer screening tends to be burdensome, invasive, and expensive, especially for a comprehensive multi-organ check. Improving the rate and effectiveness of routine cancer screenings remain a challenge in health care. Multi-cancer early detection (MCED) is an exciting concept and a potentially effective solution for addressing current issues with routine cancer screening. In recent years, several technologies have matured for MCED, such as identifying cell-free tumor DNA in blood or using organisms such as Caenorhabditis elegans as a tool for early cancer detection. In Japan, N-NOSE is a commercially available multi-cancer detection test based on the chemotaxis of C. elegans using a urine sample showing 87.5% sensitivity and 90.2% specificity. In this review, we focus on using C. elegans as a powerful biosensor for universal cancer screening. We review N-NOSE clinical research results, spotlighting it as an effective primary cancer screening test.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据